PharmaCielo (PCLOF)
OTHER OTC:PCLOF
PCLOF Stock Chart & Stats
$0.01
<$0.01(6.14%)
At close: 4:00 PM EST
$0.01
<$0.01(6.14%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.12
Previous CloseN/A
Volume1.75K
Average Volume (3M)9.90K
Market Cap
$6.67M
Enterprise Value$29.64M
Total Cash (Recent Filing)$289.24K
Total Debt (Recent Filing)$18.65M
Price to Earnings (P/E)5.2
Beta-1.64
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding187,983,690
10 Day Avg. Volume17,743
30 Day Avg. Volume9,897
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market Cap4.45
Enterprise Value/Revenue11.35
Enterprise Value/Gross Profit39.18
Enterprise Value/Ebitda-29.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Vertical Integration & Cultivation FootprintOwning cultivation and processing in Colombia provides a durable structural advantage: lower-cost production, control over supply chain, and regulatory positioning for medical cannabinoids. This supports consistent input quality and long-term contract capability versus pure resellers.
Positive Product-level Gross MarginA ~29% gross margin indicates the core product economics are viable: unit-level profitability can sustain operations if volumes rise. With fixed-cost absorption and scale, this margin provides a foundation for moving toward operating profitability over multiple quarters.
Improving Cash Burn TrendMaterial reduction in cash outflows versus prior years shows management execution on cost control and cash stewardship. A sustained improvement in burn rate lowers near-term refinancing urgency and creates runway to execute strategic initiatives if maintained.
Bears Say
Declining And Volatile RevenueFalling and inconsistent revenue undermines the company’s ability to leverage positive gross margins and cover fixed costs. Persistent top-line weakness signals demand, pricing, or distribution challenges that threaten sustainable recovery and long-term margin expansion.
Negative Equity And High LeverageSignificantly negative equity and elevated debt relative to assets create structural solvency and refinancing risk. This constrains strategic flexibility, increases cost of capital, and raises the likelihood of dilutive or disruptive financing if cash generation does not improve sustainably.
Persistent Negative Operating & Free Cash FlowOngoing negative operating and free cash flow means the company cannot self-fund operations, debt service, or reinvestment. Even with improved burn, persistent deficits require external funding, which is a structural execution and dilution risk over the medium term.
PharmaCielo News
PCLOF FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $6.67M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 37 days.
How were PharmaCielo’s earnings last quarter?
PharmaCielo released its earnings results on Mar 02, 2026. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of N/A by $0.001.
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
PharmaCielo reported an EPS of $0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
Options Prices
Currently, No data available
---